Praluent Cost in Rhode Island 2026: Prices, Coverage, and Savings Options

What Does Praluent Actually Cost in Rhode Island Right Now?

The cash-pay price for Praluent at Rhode Island retail pharmacies sits at approximately $580 per month in 2026, matching the national manufacturer list price set by Regeneron and Sanofi. That figure covers a 30-day supply of either the 75 mg or 150 mg prefilled syringe dosed every two weeks. Very few patients pay the full list price.

Commercial insurance typically negotiates a lower contracted rate, and the Regeneron/Sanofi co-pay assistance card can reduce out-of-pocket costs to $0 per month for eligible patients on qualifying private insurance plans. Government-insured patients (Medicare Part D, Medicaid) are not eligible for manufacturer co-pay cards under federal anti-kickback rules, but separate paths exist for those payers.

Patients who are uninsured or underinsured have three realistic options in Rhode Island: (1) the Praluent Patient Assistance Program (PAP) administered by Sanofi, which provides the drug free of charge to patients below certain income thresholds; (2) GoodRx or similar discount platforms, which may reduce the retail price modestly though not dramatically on branded biologics; and (3) compounded alirocumab from a licensed 503A pharmacy, discussed in detail below.

The $580 list price has remained relatively stable since Sanofi voluntarily reduced Praluent's wholesale acquisition cost in 2019 from roughly $14,500 per year to approximately $5,850 per year. That reduction followed commercial payer pressure and the Institute for Clinical and Economic Review (ICER) recommendation that cost-effectiveness benchmarks required a lower price point. FDA prescribing information

Does Rhode Island Medicaid Cover Praluent?

Rhode Island Medicaid (RIte Care and Rhody Health Options) covers Praluent with a prior authorization requirement. Approval is generally granted for two clinical scenarios: heterozygous familial hypercholesterolemia (HeFH) confirmed by genetic testing or by clinical criteria such as a Dutch Lipid Clinic Network score of 6 or higher, and established atherosclerotic cardiovascular disease (ASCVD) in patients who have not reached LDL-C targets on maximally tolerated statin therapy plus ezetimibe. NCBI: PCSK9 inhibitor access and utilization

Prior authorization requests typically require:

• Documentation of current and prior statin therapy, including doses and duration
• LDL-C values on and off therapy (usually two readings)
• Diagnosis code for HeFH or established ASCVD (recent MI, stroke, or peripheral arterial disease)
• Prescriber attestation that the patient has trialed at least one high-intensity statin at maximally tolerated dose

Rhode Island Medicaid's formulary review cycle runs annually, and coverage criteria for PCSK9 inhibitors have loosened incrementally since the 2018 publication of ODYSSEY OUTCOMES. Denials can be appealed; the clinical evidence base for alirocumab in ASCVD is strong enough that a well-documented appeal has a reasonable chance of success.

What the Evidence Says About Who Should Get PCSK9 Inhibition

ODYSSEY OUTCOMES enrolled 18,924 patients with recent acute coronary syndrome (ACS) and followed them for a median of 2.8 years. Alirocumab 75 mg every two weeks (titrated to 150 mg if needed) reduced major adverse cardiovascular events (MACE) by 15% relative to placebo (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001). All-cause mortality was also lower in the alirocumab group (3.5% vs. 4.1%). NEJM 2018, ODYSSEY OUTCOMES

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with very high-risk ASCVD, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is reasonable." That specific threshold of 70 mg/dL is the number Medicaid prior authorization reviewers in Rhode Island will look for in the chart. ACC/AHA Guideline

Is Compounded Alirocumab Legal in Rhode Island?

Yes. Rhode Island-licensed 503A compounding pharmacies may legally prepare alirocumab for individual patients under a valid prescription. 503A pharmacies operate under state pharmacy board oversight and compound on a patient-specific basis rather than in bulk, which distinguishes them from 503B outsourcing facilities. FDA: 503A vs 503B compounding

The legal pathway works like this. A licensed prescriber in Rhode Island writes a prescription for compounded alirocumab, specifying the concentration, volume, and injection schedule. The 503A pharmacy sources pharmaceutical-grade active pharmaceutical ingredient (API), compounds the preparation, and dispenses it directly to the patient. The compounded product is not FDA-approved, meaning it has not undergone the same manufacturing quality review as brand Praluent, but the prescribing physician can determine that a compounded version is appropriate when the brand drug is unavailable or cost-prohibitive for a specific patient.

Cost for compounded alirocumab varies by pharmacy. Some 503A pharmacies in the Northeast charge substantially below the $580/month list price for brand Praluent, with some patients reporting costs below $100/month depending on dose and volume. HealthRX clinical advisors recommend patients request a Certificate of Analysis (CoA) from any 503A pharmacy to confirm API purity and sterility testing before use.

Prescribers should document the medical necessity for compounding in the patient chart. The Rhode Island Board of Pharmacy follows the FDA's 2023 draft guidance that compound preparations may be dispensed when there is a "clinical difference" or documented patient need, which typically includes cost-related inability to access the brand drug. FDA draft guidance on compounding

One practical caution: compounded alirocumab formulations vary in concentration and excipient composition. Patients should confirm injection technique and storage requirements with the dispensing pharmacy, as these may differ from the brand-name pre-filled syringe they may have used previously.

Which Insurance Plans Cover Praluent in Rhode Island?

Coverage varies meaningfully across plan types, but most major commercial insurers operating in Rhode Island include Praluent on their formularies at Tier 3 or Tier 4, meaning it is covered but with higher cost-sharing than generic statins.

Major insurers with Rhode Island market presence that have historically covered PCSK9 inhibitors include Blue Cross Blue Shield of Rhode Island, Tufts Health Plan (now Point32Health), and UnitedHealthcare. Each uses prior authorization criteria that closely follow ACC/AHA guideline thresholds. LDL-C above 70 mg/dL despite maximally tolerated statin plus ezetimibe is the most common approval trigger for ASCVD patients. HeFH patients may qualify with a lower statin-failure requirement.

Medicare Part D plans cover Praluent with significant variation by plan. The 2026 Medicare Part D restructuring under the Inflation Reduction Act capped out-of-pocket drug spending at $2,000 per year for all Part D enrollees, which substantially changes the math for high-cost branded drugs like alirocumab. Patients who previously faced $5,000+ annual out-of-pocket costs under Part D may now reach the cap early in the year and pay nothing for the remainder. CMS: IRA Part D changes

Rhode Island ACA marketplace plans must cover drugs with USPSTF A or B ratings without cost-sharing. Alirocumab does not currently hold a standalone USPSTF rating, so marketplace plans have discretion in tier placement and cost-sharing structures.

Step Therapy Requirements

Many Rhode Island commercial plans impose step therapy, requiring proof that the patient has tried and failed (or cannot tolerate) at least two statins and ezetimibe before Praluent will be authorized. Some plans additionally require a trial of bempedoic acid (Nexletol), which received an FDA indication for cardiovascular risk reduction in 2023. Prescribers who anticipate step therapy should document intolerance or inadequate response to these agents in the chart at the time of the Praluent prescription, rather than waiting for a denial letter.

How the Regeneron/Sanofi Praluent Savings Card Works in Rhode Island

The Praluent co-pay card is available to commercially insured patients in Rhode Island who are not enrolled in federal or state government insurance programs. The card can reduce monthly out-of-pocket cost to as low as $0 for qualifying patients, with a maximum annual savings of up to $3,600 under the current program terms. Praluent savings program

Enrollment is done online or through the prescribing physician's office. The card works like a secondary payer at the pharmacy: the patient's insurance pays its contracted amount, and the savings card covers the remaining patient cost-sharing up to the program cap. Patients with high-deductible plans may see the largest benefit, as the card applies during the deductible phase as well as after.

Patients who lose commercial insurance eligibility (for example, after a job change that puts them onto Medicaid or Medicare) must stop using the co-pay card immediately. Using a manufacturer co-pay card while on government insurance is a federal compliance violation with serious legal consequences for both the patient and the prescriber.

What To Do If the Savings Card Is Not Enough

For patients who remain cost-burdened after the savings card, the Sanofi Patient Assistance Program (PAP) accepts applications from uninsured or underinsured Rhode Island residents. Income eligibility typically falls below 400% of the federal poverty level, though the program uses a case-by-case review. Applications are available through the prescriber's office or directly at sanofi.com/patient-support. Approval typically takes two to four weeks and provides brand Praluent at no cost for up to one year, with annual renewal.

NeedyMeds and RxAssist both list the Praluent PAP with current contact information and updated eligibility criteria.

Can I Get a Praluent Prescription via Telehealth in Rhode Island?

Yes. Rhode Island permits telehealth prescribing of Praluent. The state follows the interstate compact rules for medical licensure (Rhode Island joined the Interstate Medical Licensure Compact in 2017), meaning a physician licensed in another compact state may prescribe to Rhode Island patients via telehealth if they hold or obtain an expedited IMLC license. IMLC member states

For the initial Praluent prescription, a telehealth encounter is legally sufficient in Rhode Island as long as the prescriber conducts an appropriate clinical evaluation, reviews recent lipid panels (drawn no more than 12 months prior is a reasonable standard), and documents the clinical indication and prior therapy. No in-person physical examination is required by Rhode Island statute for this medication category.

HealthRX clinicians follow a structured telehealth intake for alirocumab prescribing that includes review of a current lipid panel, cardiac history, statin tolerance history, and current medications. Patients in Rhode Island can complete this intake, receive a prescription if clinically appropriate, and have the drug shipped to their home or sent to a local pharmacy. Injection training is provided through a short video module and can be supplemented by a nurse telephone consultation.

Telehealth prescribing does not change insurance coverage rules. Patients still need the same prior authorization documentation regardless of whether the prescription originates from an in-person or virtual visit.

What Clinical Evidence Supports Alirocumab for LDL Reduction?

Alirocumab is a fully human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). By blocking PCSK9, it prevents the degradation of LDL receptors on hepatocytes, increasing the liver's capacity to clear LDL-C from the bloodstream. The result is a dose-dependent LDL-C reduction averaging 45 to 60% from baseline across the major trials. Mechanism review, PubMed

ODYSSEY LONG TERM (N=2,341 to 78 weeks) showed a 61.9% reduction in LDL-C vs. placebo with alirocumab 150 mg every two weeks, with an LDL-C of 48 mg/dL in the treatment arm versus 119 mg/dL in the placebo arm at week 24. Injection-site reactions occurred in 5.9% of alirocumab patients vs. 4.2% of placebo patients, which represents the primary notable adverse effect in that trial. ODYSSEY LONG TERM

As noted above, ODYSSEY OUTCOMES demonstrated a cardiovascular mortality benefit in post-ACS patients. The absolute risk reduction for MACE over the 2.8-year median follow-up was 1.6 percentage points (number needed to treat approximately 63 over 2.8 years). The survival benefit was most pronounced in the subgroup with baseline LDL-C of 100 mg/dL or higher, with a hazard ratio of 0.76 for that subgroup. ODYSSEY OUTCOMES

The 2021 ESC Guidelines on Cardiovascular Disease Prevention recommend that very-high-risk patients achieve an LDL-C below 55 mg/dL. For many post-ACS patients already on maximally tolerated statins, that target is unreachable without PCSK9 inhibition. The 55 mg/dL threshold is increasingly referenced in U.S. prior authorization appeals even though the ACC/AHA guideline uses 70 mg/dL as the U.S. action threshold. ESC 2021 CVD prevention guidelines

How Does Alirocumab Compare to Evolocumab for Rhode Island Patients?

Both alirocumab (Praluent) and evolocumab (Repatha) are FDA-approved PCSK9 inhibitors with comparable LDL-C reduction profiles. The choice between them in Rhode Island often comes down to formulary tier placement and prior authorization ease rather than clinical differences.

Some Rhode Island commercial plans place evolocumab on a preferred tier relative to alirocumab, or vice versa, depending on the plan's rebate contract with the manufacturer. Prescribers should check the specific plan formulary before writing the prescription. If both are covered at the same tier, alirocumab's twice-monthly dosing (75 mg or 150 mg every 2 weeks) and evolocumab's once-monthly option (420 mg monthly via auto-injector) may influence patient preference. The monthly auto-injector may appeal to patients who prefer fewer injections.

FOURIER (evolocumab, N=27,564) and ODYSSEY OUTCOMES (alirocumab, N=18,924) are not directly comparable due to differing populations and endpoints, but both showed statistically significant MACE reductions with PCSK9 inhibition. FOURIER trial

Practical Steps for Rhode Island Patients Seeking Praluent in 2026

Getting Praluent covered and affordable in Rhode Island follows a defined sequence. Start with a current fasting lipid panel. Confirm your LDL-C is above guideline thresholds (70 mg/dL for ASCVD patients, or genetic/clinical HeFH criteria). Verify your current statin dose is maximally tolerated and that ezetimibe has been tried. Then contact a prescriber, either in-person or via telehealth, who can write the prior authorization paperwork.

Simultaneously, verify your insurance plan's formulary tier for Praluent. If covered, apply for the savings card the same day the prescription is written to avoid a gap in coverage. If prior authorization is denied, request the specific denial criteria in writing and appeal with LDL-C lab values, statin trial documentation, and references to ODYSSEY OUTCOMES and the ACC/AHA 70 mg/dL threshold.

If commercial coverage is unavailable and the Medicaid PA process is lengthy, a 503A-compounded alirocumab prescription may bridge the gap while the insurance process resolves. Document the bridge therapy in the chart.

Patients with an LDL-C of 190 mg/dL or higher on a background of HeFH diagnosis should note that the FDA label allows Praluent initiation without prior statin failure in this population, which streamlines the prior authorization argument considerably.